Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Non-Current Liabilities (2021 - 2025)

Abeona Therapeutics has reported Other Non-Current Liabilities over the past 10 years, most recently at $18.9 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $18.9 million for Q4 2025, down 40.96% from a year ago — trailing twelve months through Dec 2025 was $18.9 million (down 40.96% YoY), and the annual figure for FY2025 was $18.9 million, down 40.96%.
  • Other Non-Current Liabilities for Q4 2025 was $18.9 million at Abeona Therapeutics, down from $22.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ABEO hit a ceiling of $32.0 million in Q4 2024 and a floor of $200000.0 in Q1 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $18.9 million (2025), compared with a mean of $15.4 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 13461.0% in 2023 and later tumbled 97.43% in 2024.
  • Abeona Therapeutics' Other Non-Current Liabilities stood at $9.0 million in 2021, then surged by 118.24% to $19.7 million in 2022, then skyrocketed by 59.5% to $31.4 million in 2023, then rose by 2.11% to $32.0 million in 2024, then plummeted by 40.96% to $18.9 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $18.9 million (Q4 2025), $22.6 million (Q3 2025), and $30.2 million (Q2 2025) per Business Quant data.